Skip to main content

Table 3 Summary of Riede et al.’s results on the effect of larch arabinogalactan on common cold

From: Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials

Population analysed FASa PPa set
Groups Placebo AGa Placebo AGa
Number of common cold episodes 1.06 ± 0.85 0.83 ± 0.82 1.10 ± 0.85 0.85 ± 0.82 *
Number of subjects affected by a cold episode 72.4 % 58.4 % * 74.4 % 59.8 % *
Duration of common cold episodes 8.3 ± 2.9 8.5 ± 2.8 - -
Intensity of symptoms after 5 days, documented in CRFa 8.5 ± 6.6 8.4 ± 6.8 - -
Intensity of symptoms after 5 days, from subject diary 5.85 ± 8.35 4.73 ± 8.08 - -
Intensity of symptoms at start, documented in CRFa 11.6 ± 6.3 13.3 ± 6.6 - -
Intensity of symptoms at start, from subject diary 11.5 ± 6.5 13.7 ± 6.9 * - -
  1. a AG Arabinogalactan, CRF Case Report Form, FAS Full analysis set, PP Per protocol
  2. Mean values (± SD) significantly different from the placebo: * p < 0.05